Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]

Affiliations

• ¹ Department of Urology, Münster University Medical Center, Münster, Germany. Electronic address: martin.boegemann@ukmuenster.de.
• ² Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.
• ³ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
• ⁴ Tampere University Hospital and Tampere University, Tampere, Finland.
• ⁵ Institute of Oncology, Vilnius University, Vilnius, Lithuania.
• ⁶ Department of Urology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
• ⁷ Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus.
• ⁸ Department of Urology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
• ⁹ Hospital Erasto Gaertner, Curitiba, Brazil.
• ¹⁰ Hertsen Moscow Oncology Research Institute, Moscow, Russia.
• ¹¹ Hopital Foch, Suresnes, France.
• ¹² University Hospital Magdeburg, Magdeburg, Germany.
• ¹³ Bayer Consumer Care AG, Basel, Switzerland.
• ¹⁴ Bayer HealthCare, Loos, France.
• ¹⁵ Bayer HealthCare, Whippany, NJ, USA.
• ¹⁶ Orion Corporation Orion Pharma, Espoo, Finland.
• ¹⁷ Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.